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Purpose: To determine the recommended phase 2 dose of RRx-001, a radiosensitizer with vascular normalizing properties,
when used with whole-brain radiation therapy (WBRT) for brain metastases and to assess whether quantitative changes in
perfusion magnetic resonance imaging (MRI) after RRx-001 correlate with response.
Methods and Materials: Five centers participated in this phase 1/2 trial of RRx-001 given once pre-WBRT and then twice
weekly during WBRT. Four dose levels were planned (5 mg/m2, 8.4 mg/m2, 16.5 mg/m2, 27.5 mg/m2). Dose escalation was
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managed by the time-to-event continual reassessment method algorithm. Linear mixed models were used to correlate change
in 24-hour T1, Ktrans (capillary permeability), and fractional plasma volume with change in tumor volume.
Results: Between 2015 and 2017, 31 patients were enrolled. Two patients dropped out before any therapy. Median age was
60 years (range, 30-76), and 12 were male. The most common tumor types were melanoma (59%) and non-small cell lung
cancer (18%). No dose limiting toxicities were observed. The most common severe adverse event was grade 3 asthenia (6.9%,
2 of 29). The median intracranial response rate was 46% (95% confidence interval, 24-68) and median overall survival was
5.2 months (95% confidence interval, 4.5-9.4). No neurologic deaths occurred. Among 10 patients undergoing dynamic
contrast-enhanced MRI, a reduction in Vp 24 hours after RRx-001 was associated with reduced tumor volume at 1 and 4
months (P  .01).
Conclusions: The addition of RRx-001 to WBRT is well tolerated with favorable intracranial response rates. Because activity
was observed across all dose levels, the recommended phase 2 dose is 10 mg twice weekly. A reduction in fractional plasma
volume on dynamic contrast-enhanced MRI 24 hours after RRx-001 suggests antiangiogenic activity associated with longer-
term tumor response.  2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Brain metastases are the most frequent intracranial neo-
plasms in adults and the most common neurologic
complication of cancer. One-third to one-half of patients
with brain metastases die of neurologic deterioration, and
control of intracranial disease is correlated with increased
survival.1,2 However, systemic disease is most often the
primary cause of death.
The standard of care for patients with 1 to 3 brain me-
tastases otherwise eligible for local therapy is stereotactic
radiosurgery (SRS) or, in select patients, surgery combined
with SRS.3-6 The addition of adjuvant whole-brain radia-
tion therapy (WBRT) to local therapy reduces intracranial
relapses and neurologic deaths,2,7 and WBRT remains a
standard of care for patients with >3-4 brain metastases
and reasonable life expectancy. However, its efficacy may
be limited in more radioresistant tumor types such as
melanoma, in which uncontrolled intracranial disease and
subsequent neurologic death remain an unaddressed
issue.8,9
RRx-001 is a small molecule dinitroazetidine10 whose
potential radiosensitizing effects have been attributed to its
effects on tumor vasculature and generation of nitric oxide
(NO), an oxygen mimetic,11 under hypoxic conditions
endemic to tumors.12 RRx-001 has also been shown pre-
clinically to significantly increase tumor blood perfusion
and to synergize with radiation therapy, likely secondary to
enhanced oxygen delivery in the absence of neurotoxicity.13
A phase 1 study in adult patients with advanced malig-
nancies refractory to standard therapy demonstrated the
feasibility and safety of RRx-001 as a single agent in doses
of 10 mg/m2 to 83 mg/m2 with the absence of a maximally
tolerated dose (MTD) or any dose-limiting toxicities
(DLT).14
On the basis of its favorable toxicity profile and multiple
preclinical studies demonstrating its potential activity as a
radiosensitizer,15 both systemically and in the brain, and as
a normalizer of blood flow to gliomas,16,17 the BRAIN-
STORM study was undertaken to determine the safety and
efficacy of RRx-001 in combination with WBRT. Given the
previously observed effects on tumor blood perfusion in
systemically treated tumors, corollary dynamic contrast-
enhanced (DCE) magnetic resonance imaging (MRI) was
performed to evaluate tumor-level effects on blood perfu-
sion after treatment and whether quantitative changes after
RRx-001 correlated with longer-term tumor response.
Methods and Materials
Study design
The trial was open to accrual at 5 medical centers: The
University of Michigan (Ann Arbor, Michigan), Henry
Ford Allegiance Health (Jackson, Michigan), Providence
St. John’s Health Center (Santa Monica, California),
Washington University School of Medicine (St. Louis,
Missouri), and The Cancer Institute of New Jersey/Rutgers
University (New Brunswick, New Jersey). The trial was
registered at ClinicalTrials.gov (NCT02215512). The
institutional review boards of all participating institutions
approved the study, which was conducted according to the
provisions of the Declaration of Helsinki and the Good
Clinical Practice Guidelines of the International Confer-
ence on Harmonization. Voluntary informed consent was
obtained from all patients.
Eligibility criteria
This was a single-arm, open-label, multi-institutional
phase 1/2 dose-escalation study in patients 18 years or
older with a histologic diagnosis of solid tumor malig-
nancy and radiographic evidence of 1 or more brain
metastases on contrast-enhanced computed tomography
(CT) or MRI of the brain. Additional eligibility criteria
included an Eastern Cooperative Oncology Group
Volume 107  Number 3  2020 Phase 1/2 study of RRx-001 and radiation 479
performance status of 0 to 2, life expectancy of at least 12
weeks, adequate hematologic, hepatic, and renal function
as defined by hemoglobin 9 g/dL, absolute neutrophil
count 1000 cells/mm3, platelet count 50,000 cells/
mm3, creatinine 1.5 times the upper limit of normal
(ULN) or a measured or calculated creatinine clearance
of 50 mL/min, bilirubin 1.5 times ULN, alanine
aminotransferase and aspartate aminotransferase 5
times ULN, and alkaline phosphatase <2.5 times ULN
(5 times ULN with hepatic metastases).
Exclusion criteria included prior WBRT (prior radio-
surgery was allowed); other systemic therapy within 2 weeks
of first dose of study drug or required within 28 days from
completion of treatment; prior RRx-001 therapy; unresolved
toxicity higher than Common Terminology Criteria for
Adverse Events (version 4.0) grade 1 attributed to prior
therapy/procedure, excluding alopecia and hypothyroidism;
serious comorbidities or findings on history, examination, or
laboratory results that the investigator believed could inter-
fere with study conduct or place the patient at unacceptable
risk; inability to complywith study procedures or evaluations;
and pregnancy or lactation. All patients were required to use
acceptable methods of contraception for the duration of the
study and for 28 days after withdrawal from study.
Treatment
Patients underwent standard CT simulation with immobi-
lization in a thermoplastic mask for daily treatment. WBRT
was 30 Gy in 3 Gy fractions delivered over 2 weeks using
standard 6 MV photon opposed lateral fields.
RRx-001 was delivered on day 4  2 days before the
initiation of WBRT. It was then administered twice weekly
on days 1, 4, 8, and 11 (1 day) during the course of
WBRT and before radiation treatment on infusion days
(Fig. 1). For the first 9 patients, RRx-001 was given directly
intravenously, but owing to localized discomfort and
vasodilation on infusion due to localized NO release, the
study was amended to change the method of administra-
tion. All subsequent patients received ex vivo mixed anti-
coagulated autologous blood (12 mL), which induced the
NO release before administration. The RRx-
001eautologous blood mixture was then given intrave-
nously within 1 hour from the time of blood collection to
minimize risk of contamination (Appendix E1; available
online at https://doi.org/10.1016/j.ijrobp.2020.02.639).
After preliminary data demonstrated potential synergy
between RRx-001 and temozolomide, a subsequent study
amendment allowed concurrent (75 mg/m2 daily during
WBRT) and adjuvant (200 mg/m2 on days 1-5 of a 28-day
cycle) delivery of temozolomide with RRx-001. Seven
patients were treated on this amendment.
Dose escalation
The primary objective was to determine the MTD associated
with a 20% probability of DLT. Four dose levels were
planned for twice weekly administration (5 mg/m2, 8.4 mg/
m2, 16.5 mg/m2, 27.5 mg/m2), which was amended to a
similar flat twice weekly dosing scheme (10 mg, 17 mg, 33
mg, 55 mg) when the method of intravenous administration
changed. The first patient was treated at RRx-001 dose level
1. Each subsequent patient’s dose level was assigned using
the time-to-event continual reassessment method algo-
rithm.18,19 When a new patient was enrolled, the probability
of toxicity at each dose was estimated, based on the toxicity
data accrued up to that time, using a 1-parameter logistic
dose-toxicity model. The patient was assigned to the highest
dose with estimated probability of toxicity closest to the
target rate of 20% but not exceeding 25%, subject to 2 dose-
escalation restrictions: (1) no previously untried dose levels
could be skipped, and (2) at least 2 patients must have
completed the prior dose level before a patient could be
treated at the next dose level. Dose escalation was resumed
from dose level 1 after the study amendment using the
modified method of intravenous administration.
Safety assessments
All patients who received at least 1 dose of study treatment,
defined as RRx-001 and/or WBRT, comprised the safety
analysis population. All treatment-emergent adverse events
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Fig. 1. Study design.
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(AEs) were evaluated, coded, and assigned a grade using
the National Cancer Institute Common Toxicity Criteria
version 4.03. An AE was considered treatment emergent if
it increased in severity over the baseline severity grade and
if the date of onset occurred after enrollment but no more
than 28 days after the last dose of study treatment. DLTwas
defined as any grade 3 or higher toxicity possibly, probably,
or definitely related to RRx-001 treatment. The attribution
and relationship of the event to RRx-001 was assessed by
the investigator. AEs attributed to WBRT alone were not
considered DLTs.
Efficacy assessments
Secondary objectives included best intracranial overall
response rate (ORR, complete response [CR] and partial
response [PR]) and overall survival (OS). Response was
assessed using modified Response Evaluation Criteria in
Solid Tumors 1.1 because the study was initiated before the
availability of the Response Assessment in Neuro-
Oncology Brain Metastases Criteria20 were available. A
CR was defined as complete resolution of all enhancing
target lesions. A PR was defined as at least a 30% reduction
in the sum of the longest diameters of enhancing target
lesions compared with baseline sum of longest diameters
and an absolute decrease of at least 5 mm in at least 1 target
lesion. Progressive disease was defined as an increase of
20% in the sum of the longest diameters of target lesions,
taking as reference the smallest sum on study and an ab-
solute increase in size of at least 5 mm in at least 1 target
lesion, or the appearance of 1 or more new lesions at least 6
mm in size. All other evaluations were reported as stable
disease (SD). Lesions that had received prior radiosurgery
or were nonenhancing and primarily hemorrhagic were not
considered evaluable for RECIST response.
There were 22 patients treated with WBRT þ RRx-001
alone with sufficient efficacy data (OS and ORR), and the
Kaplan-Meier method was used to derive an estimate of the
median and its corresponding 95% confidence interval (CI).
ORR was estimated by counting the number of patients
experiencing a CR or PR. Patients with at least 1 docu-
mented response assessment were included in the analysis
of antitumor activity.
Statistical analyses were performed using R Core Team
(2013). Statistical inferential tests benchmarking uses a .05
2-sided significance level. CI estimates were 2 sided and set
at 95%.
Advanced MRI correlation
Patients enrolled at The University of Michigan underwent
correlative DCE MRI at baseline (within 21 days before the
first dose of RRx-001), within 24 hours after the first dose
of RRx-001 but before WBRT, at the end of WBRT but
before the last fraction of RT, and 1 month and 4 months
after completion of WBRT. Patients remained off standard-
of-care systemic therapies for all imaging time points from
at least 2 weeks before the baseline scan, up to and
including 1 month post-WBRT, to eliminate confounding
effects of other nonprotocol therapies.
MRI acquisition and image processing
All MRI scans were performed on a 3T scanner (Skyra,
Siemens Healthineers, Erlangen, Germany) using a 20-
channel head coil in the Department of Radiation Oncology
at The University of Michigan. Conventional 3-dimensional
pre- and postcontrast T1-weighted images and 2-
dimensional T2- fluid-attenuated inversion recovery im-
ages were acquired.
DCE images were acquired by a 3-dimensional gradient
echo pulse sequence, called TWIST, in the sagittal orien-
tation to avoid in-flow effect and ensure arterial coverage
for input function delineation. The details of image acqui-
sition and processing have been previously published in an
unrelated advanced imaging study using the same
method.21 Briefly, a 3-parameter Tofts model was used to
quantify DCE MRI to obtain the fractional plasma volume
(Vp), transfer constant of contrast (K
trans), and fractional
volume of extravascular extracellular space (ve)
22 and was
implemented using an in-house functional image analysis
tool (imFIAT).23-26 Vp is directly related to cerebral blood
volume (a density measurement) by unit conversion, and
Vp, cerebral blood volume, and cerebral blood flow are
highly correlated in brain tumors.27 A full characterization
of the performance of software using digital reference ob-
jects with a large range of physiologic parameters, acqui-
sition parameters, and added Gaussian noise has been
previously published.23
Image review and volume delineation
MRI scans at all acquired time points were centrally
reviewed with the study neuroradiologist. Lesions were
delineated on the T1-weighted postgadolinium image at
each time point. The mean T1, Vp, K
trans, and Ve in each
lesion at each time point were calculated.
Statistical analysis of imaging study
Mixed effect regression models were used to assess the
relation between baseline or during-treatment imaging
features and later changes in tumor volume. Subject-
specific random effects were included to account for
possible correlation between multiple tumors within a pa-
tient. A stepwise model-building approach with a P value
threshold of .05 was used to build a multivariable model in
which all included terms were jointly significant. Potential
covariates included RRx-001 dose level and baseline 24-
hour post-RRx change (compared with baseline) and end
of WBRT þ RRx change (compared with baseline) in
quantitative T1, Ktrans, and Vp.
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Results
Study population
Between February 2015 and February 2017, 31 patients
were enrolled on study. Two patients dropped out at base-
line before receiving study therapy because of rapid clinical
deterioration, and 7 patients were treated on a separate
amendment with concurrent RRx-001 and temozolomide;
their tumor outcomes will be reported in a separate
publication.
Median age among the 22 evaluable patients was 60
years (standard deviation 13 years), and 12 (55%) were
male. The most common primary tumor histologies were
melanoma (59%) and non-small cell lung cancer (18%).
Demographic and baseline characteristics are summarized
in Table 1. Patients with a limited number of lesions un-
derwent WBRT on protocol per physician discretion, usu-
ally in the setting of uncontrolled systemic disease.
Melanoma was the most common tumor histology because
of referral patterns and the specialization of referring
physicians.
Toxicity
No DLTs were observed at any dose level. Five patients
were treated at dose level 3, which was the highest dose
level achieved owing to a study amendment based on pre-
clinical data showing efficacy at lower dose levels before
dose level 4 was reached (Table 2).
Among 29 patients who received at least 1 dose of RRx-
001, the majority of AEs at least possibly related to study
treatment were grade 1 (mild) to grade 2 (moderate) in
severity. The only grade 3 treatment-emergent AE 5%
was asthenia in 2 of 29 patients (6.9%), neither of which
were attributed to RRx-001. There were no grade 5 adverse
events. The most common grade 1 or 2 AEs 5% are
shown in Table E1 (available online at https://doi.org/10.
1016/j.ijrobp.2020.02.639). All grade 3 or 4 AEs are
shown in Table E2 (available online at https://doi.org/10.
1016/j.ijrobp.2020.02.639). The only AEs of any grade
5% attributed to the combination of RRx-001 and WBRT
were grade 1 to 2 infusion-related reaction in 9 of 29 pa-
tients (31%), grade 1 to 2 fatigue in 2 of 29 patients (6.9%),
and grade 1 to 2 headache in 2 of 29 patients (6.9%). There
were no grade 3, 4, or 5 treatment-related AEs.
Intracranial response assessment
In the 22 patients who completed treatment and received
only RRx-001 and WBRT, best intracranial response rates
to the treatment were as follows: 1 CR, 9 PRs, 5 SD, 1
progressive disease, and 6 nonevaluable patients (Table 3).
Among 22 evaluable patients, 13 (59%) had melanoma.
Intracranial disease control rates were 70% for patients
with melanoma (6 PR and 3 SD) and 66% for non-
melanoma tumor types (1 CR, 3 PR, and 2 SD).
Survival
Mean and median duration on study for the 15 patients
experiencing a response (CR or PR) or SD were approxi-
mately 11.3 and 5.7 months, respectively (Fig. 2).
The median survival duration for 22 evaluable patients
was 5.2 months (95% CI, 4.5-9.4). The corresponding OS
Kaplan-Meier curve is depicted in Figure 3. Intention-to-
treat (n Z 31) median survival was 5.4 months (95% CI,
Table 1 Demographics and baseline characteristics
Characteristic No. of patients (%)
Age, mean 59.2 y
(SD Z 12.9, median 59.6)
22
60 y 13 (59.1)












ECOG 0 7 (31.8)
ECOG 1 13 (59.1)
ECOG 2 2 (9.1)
Missing 0 (0.0)








Abbreviations: ECOG Z Eastern Cooperative Oncology Group;
NSCLC Z non-small cell lung cancer; SCLC Z small cell lung
cancer; SD Z standard deviation.
















1 0.009 0 8 0.05 0.001 0.070
2 0.018 0 9 0.08 0.002 0.108
3 0.027 0 5 0.11 0.003 0.144
4 0.043 0 0 0.15 0.006 0.190
Abbreviations: CI Z confidence interval; DLT Z dose limiting
toxicities.
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4.5-12.4). All patients but 1 had active extracranial disease
on initial presentation. No patients died of progression of
intracranial disease.
Correlative DCE-MRI
Twelve patients underwent correlative DCE-MRI and 2
patients were excluded from imaging analysis because of
receipt of prior SRS to all lesions and rapid clinical dete-
rioration with insufficient follow-up, respectively. Ten pa-
tients underwent DCE MRI scans with 64 total lesions
evaluable at baseline, 24 hours, and end of RT. Eight pa-
tients with 44 total evaluable lesions had available imaging
at 1 month, and 6 patients with 29 total evaluable lesions
had imaging at 4 months. Baseline characteristics of the 10
evaluable patients undergoing DCE MRI are listed in
Table 4.
On univariate analysis, only a decrease in 24-hour Vp
from baseline after a single dose of RRx-001 was
marginally associated with absolute tumor volume response
1 month after treatment (P Z 0.07, Table E3; available
online at https://doi.org/10.1016/j.ijrobp.2020.02.639).
In a stepwise multivariate model assessing factors
associated with tumor volume response, RRx-001 dose









Partial response 9 41 29




Nonevaluable 6 27 19
Overall responsey 10 46 32
Disease controlz 15 68 48
Abbreviation: ITT Z intention to treat population.
* Response was assessed at 1 and 4 months using modified RECIST
1.1. Complete response: complete resolution of all enhancing lesions.
Partial response: 30% reduction in sum of longest diameters of
enhancing target lesions vs baseline sum of longest diameters and
absolute decrease of 5 mm in at least 1 target lesion. Progressive
disease: 20% increase in sum of longest diameters of target lesions vs
smallest sum and absolute increase of 5 mm in at least 1 target lesion,
or 1 new lesion at least 6 mm. All other evaluations reported as stable
disease.
y Overall response Z complete response þ partial response
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Fig. 2. Durability of response and survival by tumor type (N Z 22).
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level and baseline 24-hour post-RRx change (compared
with baseline) and end of WBRT þ RRx change (compared
with baseline) in quantitative T1, Ktrans, and Vp were
entered. Only Vp before therapy and 24-hour change in Vp
remained significant and were retained in the model after
stepwise selection. A reduction in Vp 24 hours after RRx-
001 (before WBRT) was associated with reduced tumor
volume at 1 month (estimate 0.88; 95% CI, 0.37-1.40; P Z
.001) and 4 months (estimate 1.51; 95% CI, 0.58-2.43; PZ
.003). Likewise, a lower Vp before therapy was associated
with reduced tumor volume at 1 month (estimate 0.73; 95%
CI, 0.29-1.17; P Z .002) and 4 months (estimate 1.8; 95%
CI, 0.95-2.65; P Z .0002), suggesting antiangiogenic ac-
tivity and early potential vascular normalization after a





















All 22 19 17 7 7 5 5 4 4 4 3 3
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2
Fig. 3. Overall survival Kaplan-Meier curve (with 95% confidence interval indicated in shading; N Z 22).














1 Melanoma BRAFwt Male Yes 1 5 1.9 (0.2-10.8) ICI
2 Melanoma BRAFm Male No 1 3 0.3 (0.2-0.4) ICI
3 Melanoma BRAFm Male No 1 4 0.8 (0.3-2.7) BRAFi, ICI
4 Melanoma BRAFm Female No 1 3 0.4 (0.3-1.5) ICI, TMZ
5 NSCLC UNK Female No 2 13 0.1 (0.04-0.5) ICI
6 Breast ERþ/PRþ/
HER2þ
Female No 2 4 0.4 (0.1-1.0) Trastuzumab,
pertuzumab
7 Melanoma BRAFwt Female Yes 3 13 0.8 (0.1-10.1) None
8 Melanoma BRAFwt Female No 3 4 0.3 (0.2-0.3) ICI
9 NSCLC UNK Female Yes 3 7 0.1 (0.09-0.4) None
10 Melanoma BRAFwt Male No 3 8 0.4 (0.2-0.8) TMZ
Abbreviations: BRAFi Z BRAF inhibitor; ICI Z immune checkpoint inhibitor; NSCLC Z non-small cell lung cancer; TMZ Z temozolomide.
* Lesions evaluable at baseline (not previously irradiated); units 1/ms; units 1/min; units mL/g.
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Discussion
BRAINSTORM is the first trial to evaluate the safety and
tolerability of concurrent RRx-001 with WBRT for patients
with brain metastases. The combination was well tolerated
with no safety signals at all doses tested. No MTD was
reached, and no DLTs were observed. The majority of AEs
were mild to moderate in severity, and none resulted in
clinical trial discontinuation. Additionally, the novel
finding that early tumor blood volume reduction 24 hours
after RRx-001 was associated with longer-term tumor
response suggests early potential antiangiogenic effects of
RRx-001 at the level of tumor vasculature that may serve as
a potential biomarker of early treatment response, war-
ranting further investigation in future studies.
Potential synergy between RRx-001 and WBRT is sug-
gested by an intracranial response rate of 46% among
evaluable patients (32% among the ITT population), which
is notable because the majority of patients treated on this
study had melanoma, a typically radioresistant tumor type
in which response rates after WBRT have been reported to
be as low as 5%.28 Intracranial disease control rates among
patients with melanoma (70%) were as high as those in
patients with more radiosensitive tumor types (66%).
However, response rates beyond 1 month in this study may
have been confounded by the effect of subsequent systemic
therapies with potential intracranial activity such as im-
mune checkpoint inhibitors, which many patients received.
Overall survival was 5.2 months in this poor-prognosis
cohort with active extracranial disease, but it is notable
that no patients died of neurologic causes despite many
patients having a significant burden of presumably radio-
resistant intracranial disease.
The mechanism for the potential synergy between RRx-
001 and radiation is hypothesized, at least in part, to be
related to nitric oxide generation under hypoxic tumor
conditions and normalization of the tumor vasculature,
which may selectively enhance the effects of radiation
therapy at the tumor level.15 Tumor hypoxia as a source of
radioresistance has been well documented in preclinical
and clinical studies over many decades, with evidence of
improved locoregional tumor control with abrogation of
tumor hypoxia in certain tumor sites such as the head and
neck.29 Studies have demonstrated that upon administra-
tion, RRx-001 penetrates the red blood cell (RBC) mem-
brane and irreversibly binds to the beta Cysteine 93 residue
of hemoglobin.30 Subsequently induced RBC membrane
changes lead to increased phosphatidylserine exposure, and
RRx-001emodified RBCs are preferentially internalized
and catabolized by the endothelial cells of the microvas-
culature, releasing redox active metabolites and causing
oxidative damage.31 Studies have previously demonstrated
that RRx-001 exerts a cytotoxic effect in vitro against a
variety of human cancer cell lines, an effect that is
enhanced under hypoxic conditions.10,13 In HT29 and SCC
VII cell lines, RRx-001 induces intracellular reactive
oxygen species generation, leading to DNA damage and
tumor cell apoptosis.13 Inhibition of tumor growth was also
observed in vivo in mice bearing SCC VII tumors and
demonstrated selective tumor cell radiosensitization in vitro
and in vivo under hypoxic and normoxic tumor conditions,
with prolongation of tumor growth delay times for com-
bination therapy without a reduction in animal body weight
compared with untreated control or radiation-treated
mice.13
Our observation of tumor-level vascular effects offers a
first-time look at the potential effect of RRx-001 for met-
astatic tumors in the central nervous system. Prior pre-
clinical studies13 using microbubble-enhanced ultrasound
imaging to assess flank tumors in mouse models before and
after RRx-001 and radiation demonstrated a dramatic in-
crease in the rate of blood perfusion and blood volume of
SCC VII tumors in a dose- and time-dependent manner that
peaked 6 hours after administration of RRx-001. In this
study, we performed a lesion-level analysis of quantitative
metrics derived from DCE MRI in patients with intracranial
metastases from solid tumor malignancies. We demon-
strated a significant and consistent relationship between
reduced blood plasma volume (Vp) 24 hours after admin-
istration of RRx-001 alone and subsequent tumor volume
response; this is the first advanced imaging metric linked to
clinical response in patients with brain metastases treated
with RRx-001. A number of explanations are possible for
the observation of reduced Vp 24 hours after administration
of RRx-001 in our study, including the assessment of
metastatic brain tumors in human patients, who may exhibit
different phenotypic features at the level of brain tumor
vasculature compared with the flank tumors in mouse
subjects previously studied. Moreover, the use of quanti-
tative DCE-MRI to assess fractional plasma volume and
cerebral blood volume changes after RRx-001, as well as
the timeline (24 hours) selected for assessment in our study,
stands in contrast to the methodology used in prior pre-
clinical studies, in which ultrasound imaging of systemic
disease was acquired as early as 2 to 6 hours after RRx-001
administration.
A possible explanation for this presumed early (24 hour)
effect of RRx-001 on metastatic brain tumor response may
be related to a direct antiangiogenic effect induced through
RRx-001 catabolism and oxidative damage. Metastatic
brain tumors, like other solid tumor malignancies, depend
on vascular blood supply for outgrowth. Mechanisms of
achieving vascular nutrient supply appear to vary by tumor
histology, with melanoma brain metastases demonstrating a
tendency for a co-optive growth pattern along pre-existing
vascular structures.32,33 Whether RRx-001 induces anti-
angiogenic effects against pre-existing vascular channels in
this cohort of patients with predominantly melanoma brain
metastases was not directly evaluated in this study, but the
reduction in blood plasma volume associated with tumor
response suggests tumor vascular effects by RRx-001 in the
central nervous system that merit further investigation in
future planned studies.
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Conclusions
RRx-001 in combination with WBRT appears well toler-
ated in patients with brain metastases, with an intracranial
response rate of 46%, an intracranial disease control rate of
68%, and no neurologic deaths observed. After a single
dose of RRx-001, a reduction in Vp assessed by DCE MRI
is associated with tumor volume response at 1 month and 4
months and may potentially serve as a biomarker of longer-
term response. Because activity was observed across all
dose levels in the absence of an observed dose-response,
the recommended phase 2 dose is 10 mg administered
twice weekly.
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